SALVADORI, Severo
 Distribuzione geografica
Continente #
NA - Nord America 23.481
AS - Asia 11.352
EU - Europa 6.169
SA - Sud America 1.675
AF - Africa 241
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 12
Totale 42.950
Nazione #
US - Stati Uniti d'America 23.109
SG - Singapore 4.191
CN - Cina 3.034
UA - Ucraina 1.316
DE - Germania 1.298
BR - Brasile 1.297
VN - Vietnam 1.133
HK - Hong Kong 1.003
TR - Turchia 884
GB - Regno Unito 787
IT - Italia 738
FI - Finlandia 513
FR - Francia 407
SE - Svezia 359
RU - Federazione Russa 280
JP - Giappone 218
IN - India 205
MX - Messico 169
CA - Canada 157
BD - Bangladesh 129
AR - Argentina 122
PL - Polonia 114
ZA - Sudafrica 89
IQ - Iraq 79
BE - Belgio 78
ID - Indonesia 78
CO - Colombia 67
PK - Pakistan 63
NL - Olanda 60
EC - Ecuador 54
ES - Italia 51
UZ - Uzbekistan 47
PH - Filippine 44
VE - Venezuela 37
SA - Arabia Saudita 35
LT - Lituania 33
MA - Marocco 32
CL - Cile 30
TN - Tunisia 30
AT - Austria 24
MY - Malesia 24
AE - Emirati Arabi Uniti 23
PY - Paraguay 22
IR - Iran 21
KR - Corea 21
EG - Egitto 20
KE - Kenya 20
PE - Perù 18
CZ - Repubblica Ceca 17
JO - Giordania 17
UY - Uruguay 17
IL - Israele 16
DZ - Algeria 13
RO - Romania 13
AU - Australia 12
AL - Albania 11
CH - Svizzera 11
NP - Nepal 11
BO - Bolivia 10
ET - Etiopia 9
LB - Libano 9
BH - Bahrain 8
HN - Honduras 8
AZ - Azerbaigian 7
IE - Irlanda 7
PA - Panama 7
TH - Thailandia 7
JM - Giamaica 6
NZ - Nuova Zelanda 6
SN - Senegal 6
BG - Bulgaria 5
DO - Repubblica Dominicana 5
EU - Europa 5
HR - Croazia 5
KZ - Kazakistan 5
OM - Oman 5
QA - Qatar 5
DK - Danimarca 4
GR - Grecia 4
GT - Guatemala 4
HU - Ungheria 4
KG - Kirghizistan 4
PS - Palestinian Territory 4
PT - Portogallo 4
SV - El Salvador 4
TT - Trinidad e Tobago 4
XK - ???statistics.table.value.countryCode.XK??? 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BJ - Benin 3
CI - Costa d'Avorio 3
CR - Costa Rica 3
LV - Lettonia 3
MM - Myanmar 3
MT - Malta 3
NG - Nigeria 3
NO - Norvegia 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
Totale 42.903
Città #
Singapore 2.675
Ashburn 2.391
Fairfield 2.364
Woodbridge 2.349
Houston 1.588
Jacksonville 1.432
Ann Arbor 1.248
Chandler 1.102
San Jose 1.088
Hong Kong 990
Beijing 961
Seattle 913
Santa Clara 897
Wilmington 847
Cambridge 789
Izmir 441
Nanjing 415
Ho Chi Minh City 372
Dallas 350
Munich 310
Los Angeles 300
Princeton 276
Hanoi 258
San Diego 235
Lauterbourg 229
New York 222
Tokyo 216
Boardman 196
Dearborn 196
Milan 189
Helsinki 169
Ferrara 152
São Paulo 128
Nanchang 122
Falkenstein 117
Shenyang 116
Hefei 110
Shanghai 105
Warsaw 104
Mexico City 102
Addison 89
London 82
Falls Church 81
Turku 78
Orem 76
San Mateo 75
Brussels 73
Hebei 72
Tianjin 72
Brooklyn 68
Auburn Hills 65
Bremen 63
Jiaxing 63
Jinan 63
Changsha 61
Haiphong 57
Chicago 56
Frankfurt am Main 55
Buffalo 52
Da Nang 51
Mountain View 49
The Dalles 48
Kunming 47
Montreal 47
Moscow 46
Johannesburg 45
Toronto 44
Denver 43
San Francisco 43
Stockholm 43
Redwood City 41
Tashkent 41
Atlanta 40
Chennai 40
Washington 40
Philadelphia 39
Rio de Janeiro 39
Zhengzhou 39
Council Bluffs 38
Poplar 38
Guangzhou 36
Ningbo 35
Norwalk 35
Phoenix 35
Belo Horizonte 33
Manchester 33
Boston 32
Baghdad 29
Hải Dương 29
Columbus 28
Bologna 27
Biên Hòa 25
Dhaka 25
Medellín 25
Jakarta 24
Mumbai 24
Tappahannock 24
Curitiba 23
Des Moines 22
Mcallen 22
Totale 29.832
Nome #
[Nphe(1),Arg(14),Lys(15)]nociceptin-NH2, a novel potent and selective antagonist of the nociceptin/orphanin FQ receptor 391
AGONISTI PIENI E PARZIALI ED ANTAGONISTI DEL RECETTORE PER NOCICETTINA/ORFANINA FQ AD ELEVATA POTENZA” 335
Design, synthesis and biological characterization of novel mitochondria targeted dichloroacetate-loaded compounds with antileukemic activity 324
A diastereoselective synthesis of Cebranopadol, a novel analgesic showing NOP/mu mixed agonism 291
A novel and facile synthesis of tetra branched derivatives of nociceptin/orphanin FQ 285
A cyclic peptide T analogue with high chemotactic activity 281
A new selective antagonist of the nociceptin receptor 269
[(pF)Phe4,Arg14,Lys15]N/OFQ-NH2 (UFP-102), a highly potent and selective agonist of the nociceptin/orphanin FQ receptor 268
In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor 257
Blockade of nociceptin/orphanin FQ receptor signaling in rat substantia nigra pars reticulata stimulates nigrostriatal dopaminergic transmission and motor behavior 256
A new ligand for the urotensin II receptor 251
[Dmt(1) ]N/OFQ(1-13)-NH(2) , a potent nociceptin/orphanin FQ and opioid receptor universal agonist. 251
[D-Pen(p-tBuBzl)5]NPS, a novel ligand for the neuropeptide S receptor: structure activity and pharmacological studies 242
2-Bromoamides as Synthons for Pseudopeptides Containing Aminodicarboxy Units 239
Dermorphin, a new opioid peptide, stimulates thyrotropin secretion in normal subjects 237
Structure-and conformation-Activity studies of nociceptin/orphanin FQ receptor dimeric ligands 237
[(t)Bu-d-Gly(5)]NPS, a pure and potent antagonist of the neuropeptide S receptor: In vitro and in vivo studies 236
N- and C-terminal modifications of nociceptin/orphanin FQ generate highly potent NOP receptor ligands 235
Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4′-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide 234
Structure activity studies of nociceptin/orphanin FQ(1–13)-NH2 derivatives modified in position 5 234
Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist 232
2-Aminoamides and Pseudopeptides Carrying an Amino Group Common to two Residues 231
Acid catalysis in the formation of dioxopiperazines from peptides containing tetrahydroisoquinoline‐3‐carboxylic acid at position 2 230
Dermorphin inhibits spinal nociceptive flexion reflex in humans 227
Address and message sequences for the nociceptin receptor: A structure-activity study of nociceptin-(1-13)-peptide amide 227
[Nphe(1)]nociceptin-(1-13)-NH2 antagonizes nociceptin effects in the mouse colon 226
Blockade of nociceptin/orphanin FQ-NOP receptor signalling produces antidepressant-like effects: pharmacological and genetic evidences from the mouse forced swimming test 226
Tryptophan replacement in the nociceptin/orphanin FQ receptor ligand Ac-RYYRWK-NH2 224
Cholinergic mediation in dermorphin-induced growth hormone secretion in man 219
Conformation-activity relationship of neuropeptide S and some structural mutants: Helicity affects their interaction with the receptor 219
UFP-112 a Potent and Long-Lasting Agonist Selective for the Nociceptin/Orphanin FQ Receptor 218
Dmt-Tic-NH-CH2-Bid (UFP-502), a potent DOP receptor agonist: In vitro and in vivo studies 217
Pharmacological characterization of the nociceptin receptor mediating hyperalgesia in the mouse tail withdrawal assay 216
Pharmacological profile of nociceptin/orphanin FQ receptors regulating 5-hydroxytryptamine release in the mouse neocortex 214
Pharmacological characterization of tachykinin tetrabranched derivatives 212
Further studies on nociceptin-related peptides: Discovery of a new chemical template with antagonist activity on the nociceptin receptor 210
Physicochemical stability of cabazitaxel and docetaxel solutions 210
N-carbamidoyl-4-((3-ethyl-2,4,4-trimethylcyclohexyl)methyl)benzamide enhances staurosporine cytotoxic effects likely inhibiting the protective action of Magmas toward cell apoptosis 209
Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24 208
Anxiolytic- and antidepressant-like activities of H-Dmt-Tic-NH-CH(CH2-COOH)-Bid (UFP-512), a novel selective delta opioid receptor agonist 208
UFP-101 antagonizes the spinal antinociceptive effects of nociceptin/orphanin FQ; Behavioral and electrophysiological studies in mice 206
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease 206
Further studies at neuropeptide S position 5: Discovery of novel neuropeptide S receptor antagonists 205
Synthesis and biological activity of human neuropeptide S analogues modified in position 2 204
Peptide welding technology – A simple strategy for generating innovative ligands for G protein coupled receptors 203
Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. 199
Neuropeptide S receptor ligands: a patent review (2005-2016) 199
Prolactin and growth hormone responses to dermorphin in patients with prolactin-secreting pituitary adenoma 199
Structure-activity study of the nociceptin(1-13)-NH2 N-terminal tetrapeptide and discovery of a nociceptin receptor antagonist 198
Opioid bifunctional ligands from morphine and the opioid pharmacophore Dmt-Tic 198
Pharmacological characterization of nociceptin receptor: an in vitro study 197
In vitro and in vivo pharmacological characterization of nociceptin/orphanin FQ tetrabranched derivatives 196
Urotensin II stimulates plasma extravasation in mice via UT receptor activation 196
Characterization of [Nphe(1)]nociceptin(1-13)NH2, a new selective nociceptin receptor antagonist 195
Opioid agonists and antagonists. Peptides containing N-terminal allyl groups and/or a thiomethylene linkage in place of a peptide bond 194
Prolactin-Releasing Activity of Dermorphin, a New Synthetic Potent Opiate-Like Peptide, in Normal Human Subjects 194
A new convenient synthetic method and preliminary pharmacological characterization of triazinediones as prokineticin receptor antagonists 193
Structure-activity study at positions 3 and 4 of human neuropeptide S. 192
Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 5: Identification of Potent and Pure Neuropeptide S Receptor Antagonists 192
Crystal structures of dipeptides containing the Dmt-Tic pharmacophore 192
Neuropeptide S is a stimulatory anxiolytic agent: A behavioural study in mice 192
Synthesis and biological activity of nociceptin/orphanin FQ analogues substituted in position 7 or 11 with C alpha,alpha-dialkylated amino acids 192
Nociceptin receptor activation inhibits tachykinergic non adrenergic non cholinergic contraction of guinea pig isolated bronchus 192
DELTA-OPIOID RECEPTOR MODULATION OF THE HYPOTHALAMIC -PITUITARY-ADRENOCORTICAL AXIS 191
Synthesis and separation of the enantiomers of the neuropeptide S receptor antagonist (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68). 188
Stimulatory effect of dermorphin, a new synthetic potent opiate-like peptide, on human growth hormone secretion 188
Critical role for prokineticin 2 in CNS autoimmunity 187
Dermorphin decreases plasma LH levels in human: Evidence for a modulatory role of gonadal steroids 186
Design of d-opioid peptide antagonists for emerging drug applications 186
In vitro and in vivo pharmacological characterization of the neuropeptide S receptor antagonist [D-Cys(tBu)5]neuropeptide S 184
Characterization of nociceptin receptors in the periphery: in vitro and in vivo studies 182
ANALOGHI DERMASEPTINICI AD ATTIVITA’ ANTIMICROBICA 182
Synthetic Approach to non-Isosteric Peptidomimetics Related to Human Endothelin 181
Antidepressant-like effects of the nociceptin/orphanin FQ receptor antagonist UFP-101: New evidence from rats and mice 180
Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein Gαqi5 179
Anxiolytic and antidepressant-like activities of UFP-512, a novel selective delta opiold receptor agonist 179
Structure-activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11) 178
Responses of plasma renin activity, aldosterone, adrenocorticotropin, and cortisol to dermorphin, a new synthetic potent opiate-like peptide, in man 178
Structure–activity relationships of cyclic and linear peptide T analogues 178
Synthesis and opioid activity of partial retro‐inverso analogs of dermorphin 178
Prokineticin 2 upregulation in the peripheral nervous system has a major role in triggering and maintaining neuropathic pain in the chronic constriction injury model 178
Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands 176
Pharmacology of [Tyr(1)]nociceptin analogs: receptor binding and bioassay studies 174
Assessment of substitution in the second pharmacophore of Dmt-Tic analogues 174
Hydrogen sulfide induced disruption of Na+ homeostasis in the cortex 174
Synthesis and biological activity of carboxyl terminally extended dermorphins 173
Structure-activity relationship study on human urotensin II 172
The SH3 domain of nebulin binds selectively to type II peptides: theoretical prediction and experimental validation 171
Nociceptin/orphanin FQ receptor ligands 171
6-N,N-dimethylamino-2,3-naphthalimide: A new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides 170
New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores 169
The nociceptin/orphanin FQ receptor antagonist, [Nphe(1)]NC(1-13)NH2, potentiates morphine analgesia 169
Somatostatin Inhibits the Dermorphin-Stimulated Thyrotropin Release in Man 169
In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen(5), DTrp(7), Dab(8)] urotensin II(4-11) (UFP-803) 169
Pharmacological profile of hemokinin 1: a novel member of the tachykinin family 168
SUPRAMOLECULAR AGGREGATES COMPRISING MALEIMIDO CORES 168
Effect of dermorphin on behavior and hippocampal electrical activity in rabbits 167
Emerging Evidence for Neurotensin Receptor 1 Antagonists as Novel Pharmaceutics in Neurodegenerative Disorders. 167
In vitro and in vivo pharmacological profile of UFP-512, a novel selective δ-opioid receptor agonist; correlations between desensitization and tolerance 167
Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors 167
Totale 20.788
Categoria #
all - tutte 183.825
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 3.184
Totale 187.009


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.058 0 0 0 0 0 0 0 0 0 417 470 171
2021/20222.994 126 290 230 211 230 135 136 170 114 228 224 900
2022/20232.733 297 96 90 335 463 380 148 272 388 16 143 105
2023/20241.291 150 183 94 32 103 233 51 82 17 22 32 292
2024/20255.005 141 106 410 141 637 458 156 346 682 512 749 667
2025/202613.908 1.509 666 1.429 2.046 2.032 995 1.674 739 1.380 1.438 0 0
Totale 43.210